Publications
Read the latest publications from LUMICKS Cell Avidity technologies & solutions
Arellano-Ballestero et al., Proteomic and phenotypic characteristics of memory-like natural killer cells for cancer immunotherapy, JITC, 2024
Guruprasad et al., The BTLA-HVEM axis restricts CAR T cell efficacy in cancer, Nature Immunology, 2024
O’Connell et al., Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma, JITC, 2024
Wang et al., Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia, Cell Reports Medicine, 2024
Carr et al., Advances in preclinical TCR characterization: leveraging cell avidity to identify functional TCRs, Biological Chemistry, 2024
Wehrli et al., Mesothelin CAR T-cells secreting anti-FAP/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma, Clin Cancer Res., 2024
Wang et al., Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects, Molecular Cancer, 2024
Boucher et al., Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia, Molecular Therapy Oncology, 2023
Bouti et al., SIGLEC-5/14 Inhibits CD11b/CD18 Integrin Activation and Neutrophil-Mediated Tumor Cell Cytotoxicity, Int. J. Mol. Sci, 2023
Uhl et al., Interferon-γ couples CD8+ T cell avidity and differentiation during infection, Nature Communications, 2023.
Sugiyarto et al., Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1. JITC, 2023.
Chockley et al. Synapse-tuned CARs enhance immune cell anti-tumor activity Nat. Biotech.,2023
Wang et al. Acoustic force-based cell–matrix avidity measurement in high throughput. Biosensors 2023
Perriello et al., IL3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML. Blood Adv., 2022
Li et al. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat. Med.,2022
Leick et al. Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell, 2022.
Larson et al. CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours. Nature, 2022
Halim et al. Engineering of an avidity-optimized CD19-specific parallel chimeric antigen receptor that delivers dual CD28 and 4-1BB co-stimulation. Front. Immunol., 2022.
Balneger et al. Sialic acid blockade in BDMCs enhances CD8+ T cell responses by facilitating high avidity DC-T cell interactions. Cell. Mol. Life Sci., 2022
Katsarou et al. Dual targeting with a CAR and a chimeric costimulatory receptor (CCR) enhances T cell sensitivity of tumor antigen recognition and persistence. Science Translational Medicine, 2021.
Fernandez de Larrea et al. Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma. Blood Cancer Discovery, 2020.
Kamsma et al. Single-Cell Acoustic Force Spectroscopy: Resolving Kinetics and Strength of T Cell Adhesion to Fibronectin. Cell Reports, 2018.
Our solution
The z-Movi® Cell Avidity Analyzer is a solution for researchers to determine cell avidity, which has been notoriously difficult to measure until now. Through avidity measurements, the z-Movi can help researchers investigate cell interaction properties that correspond to immune cell response in a predictive, reproducible, and fast manner. All this at a high-throughput and single-cell level, without compromising cell viability.
Being able to measure these interactions provides researchers valuable information and enables them to select best candidates at an early stage. This informed selection from the start can improve their success rate dramatically.
Curious to learn more?
